Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February...

Area of Science:

• Virology
• Immunology
• Infectious Diseases

Background:

• The first confirmed case of coronavirus disease (COVID-19) in Finland occurred on January 29, 2020.
• This initial case did not result in detectable secondary transmission within the community.

Purpose of the Study:

• To detail the clinical presentation and laboratory findings of the first COVID-19 case in Finland.
• To characterize the isolated SARS-CoV-2 virus strain and analyze the host's immune response.

Main Methods:

• Clinical observation and data collection from day 3 to 23 post-symptom onset.
• Isolation and genomic sequencing of the SARS-CoV-2/Finland/1/2020 virus strain.
• Serological assays to detect neutralizing antibodies, IgM, and IgG against SARS-CoV-2 antigens.

Main Results:

• The patient exhibited clinical symptoms consistent with COVID-19.
• Genomic analysis revealed a single nucleotide substitution in the Finnish strain compared to the Wuhan reference.
• A robust neutralizing antibody response, alongside specific IgM and IgG, was detected within 9 days.
• Antibodies primarily targeted the nucleocapsid and spike proteins of SARS-CoV-2.

Conclusions:

• The initial COVID-19 case in Finland was successfully managed without onward transmission.
• The study provides insights into the early clinical and immunological profile of SARS-CoV-2 infection.
• The rapid development of neutralizing antibodies highlights the potential for serological markers in early infection detection.